Stock Chart

MNKD

$3.20 +4.92%
Score: 51.4 HOLD
LEAPs: SELL $7
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $7
Premium: $1.10
Expiry: Jan 15, 2027
Target: $8
Score: -55

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.67x (vs SPY: 0.5x | vs QQQ: 0.4x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 22, 2026
Bear Pennant Bearish scenario quality 71/100
Setup invalidates on a close above $3.19 · pole −31% — no price target (measured-move targets failed our backtest for flags/pennants)
Historically breaks down 70% of the time (n=1,730). Measured-move targets failed our backtest — none shown.
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and invalidation level are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About MNKD - Mannkind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Key Statistics

Market Cap $981M

This MNKD stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track MNKD's price movements with trendlines, gamma walls, and key support/resistance levels.